company background image
4133 logo

Abnova (Taiwan) TWSE:4133 Stock Report

Last Price

NT$32.65

Market Cap

NT$2.0b

7D

0.3%

1Y

-7.2%

Updated

15 Jun, 2024

Data

Company Financials

Abnova (Taiwan) Corporation

TWSE:4133 Stock Report

Market Cap: NT$2.0b

4133 Stock Overview

Manufactures and sells various recombinant proteins and antibodies.

4133 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance2/6
Financial Health6/6
Dividends2/6

Abnova (Taiwan) Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Abnova (Taiwan)
Historical stock prices
Current Share PriceNT$32.65
52 Week HighNT$38.85
52 Week LowNT$29.80
Beta0.39
1 Month Change3.00%
3 Month Change3.65%
1 Year Change-7.24%
3 Year Change-55.15%
5 Year Change17.45%
Change since IPO-38.07%

Recent News & Updates

Recent updates

Abnova (Taiwan) Corporation (TPE:4133) Stock's On A Decline: Are Poor Fundamentals The Cause?

Feb 10
Abnova (Taiwan) Corporation (TPE:4133) Stock's On A Decline: Are Poor Fundamentals The Cause?

Shareholder Returns

4133TW Life SciencesTW Market
7D0.3%2.9%2.9%
1Y-7.2%-20.8%28.8%

Return vs Industry: 4133 exceeded the TW Life Sciences industry which returned -20.8% over the past year.

Return vs Market: 4133 underperformed the TW Market which returned 28.8% over the past year.

Price Volatility

Is 4133's price volatile compared to industry and market?
4133 volatility
4133 Average Weekly Movement2.2%
Life Sciences Industry Average Movement4.4%
Market Average Movement4.7%
10% most volatile stocks in TW Market8.4%
10% least volatile stocks in TW Market2.2%

Stable Share Price: 4133 has not had significant price volatility in the past 3 months.

Volatility Over Time: 4133's weekly volatility (2%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2002n/an/awww.abnova.com

Abnova (Taiwan) Corporation manufactures and sells various recombinant proteins and antibodies. The company’s products portfolio includes SARS-CoV/CoV-2 DNA, RNA, proteins/peptides, lysates/slides, Ab pairs/kits, Ab arrays, polyclinic antibody, beads/dyes, in situ hybridization products, systems, and automations. It also offers MaxPab, monoclonal, polyclonal, recombinant, conjugate, secondary/tag, IHC/pathology, and circulating rare cell antibodies.

Abnova (Taiwan) Corporation Fundamentals Summary

How do Abnova (Taiwan)'s earnings and revenue compare to its market cap?
4133 fundamental statistics
Market capNT$1.98b
Earnings (TTM)NT$59.69m
Revenue (TTM)NT$371.63m

33.1x

P/E Ratio

5.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
4133 income statement (TTM)
RevenueNT$371.63m
Cost of RevenueNT$201.69m
Gross ProfitNT$169.95m
Other ExpensesNT$110.26m
EarningsNT$59.69m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.99
Gross Margin45.73%
Net Profit Margin16.06%
Debt/Equity Ratio0.03%

How did 4133 perform over the long term?

See historical performance and comparison

Dividends

2.2%

Current Dividend Yield

73%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.